Working… Menu

A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01709331
Recruitment Status : Completed
First Posted : October 18, 2012
Results First Posted : May 9, 2016
Last Update Posted : September 3, 2018
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:

This study will assess if corifollitropin alfa (MK-8962), when administered in combination with human chorionic gonadotropin (hCG), will increase testicular volume in men with HH who remain azoospermic after treatment with hCG alone.

Hypothesis: The lower limit of the 95% confidence interval for the geometric mean increase in testicular volume from Day 1 to Week 52 is greater than one.

Condition or disease Intervention/treatment Phase
Hypogonadism Hypogonadotropic Hypogonadism Drug: Corifollitropin alfa Drug: hCG Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Multi-center, Open Label, Uncontrolled Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) in Inducing Increased Testicular Volume and Spermatogenesis in Adult Men With Hypogonadotropic Hypogonadism Who Remain Azoospermic When Treated With hCG Alone (Phase III; Protocol No. MK-8962-031-00 [Also Known as SCH 900962, P07937])
Actual Study Start Date : February 11, 2013
Actual Primary Completion Date : April 8, 2015
Actual Study Completion Date : April 8, 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Corifollitropin alfa 150 μg + hCG
During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
Drug: Corifollitropin alfa
Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
Other Name: MK-8962

Drug: hCG
hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)

Primary Outcome Measures :
  1. Change From Baseline in Log-Transformed Testicular Volume at Week 52 [ Time Frame: Baseline and Week 52 ]
    Participants underwent testicular ultrasound in the pretreatment phase at Weeks -16, -8, -1; and during the combined treatment phase at Baseline (predose, Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52. The testicular volume was measured as the sum of volumes of left and right testes. The mean change from Day 1 in log-transformed testicular volume was analyzed using a mixed model with a fixed effect for time point and a random effect for the participant. For each time point, the mean change from Day 1 to that time point and the associated 95% confidence interval (CI) was calculated. The geometric mean fold change in testicular volume and its 95% CI was obtained by exponentiation.

  2. Percentage of Participants With Anti-Corifollitropin Alfa Antibodies [ Time Frame: Up to Week 57 ]
    Blood samples were collected for assessment of anti-corifollitropin alfa antibodies in the pretreatment phase at Week -16 and Week -1; during the combined treatment phase at Weeks 4, 16, 28, 50, 52; and at the post-treatment follow-up visit, which could occur from Week 53 up to Week 57.

Secondary Outcome Measures :
  1. Percentage of Participants With Induced Spermatogenesis Resulting in a Sperm Count ≥1x10^6/mL at or Before Week 52 [ Time Frame: Up to Week 52 ]
    Semen samples were produced by masturbation after at least 48 hours of sexual abstinence and collected for evaluation in the pretreatment phase at Week -1, and during the combined treatment phase at Weeks 16, 28, 40, and 52.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with hypogonadotropic hypogonadism, either congenital or acquired
  • Have low circulating levels of testosterone
  • Have low circulating levels of gonadotropins (follicle stimulating hormone [FSH]; luteinizing hormone)
  • Presence of both scrotal testes
  • Have azoospermia (no measurable level of sperm)
  • Adequate replacement of other pituitary hormones
  • Good general physical and mental health

Exclusion Criteria:

  • Primary hypogonadism, such as Klinefelter's syndrome
  • History of unilateral or bilateral cryptorchidism (maldescended testes)
  • History or presence of testicular pathology of clinical importance (e.g., epididymitis, orchitis, testicular torsion, varicocele stage III, testicular atrophy, occlusive azoospermia, etc), and/or vasectomy
  • Treated with FSH, hCG or gonadotropin-releasing hormone (GnRH) within previous 3 months or for more than 1 month within previous 6 months
  • Proven spermatogenesis with hCG treatment alone
  • Previous unsuccessful attempt with hCG in combination with human menopausal gonadotropin (hMG)/FSH to achieve spermatogenesis
  • Required a dose of hCG of more than 6000 international units (IU) per week in a previous attempt to normalize T levels
  • Untreated pituitary or hypothalamic tumor, or inadequately treated pituitary or hypothalamic tumor that is likely to progress during the study
  • History or presence (known or suspected) of testicular, prostatic or breast cancer
  • Prostate pathology of clinical importance
  • Past or present oncologic treatment (chemo/radiotherapy)
  • Diabetes mellitus
  • Clinically significant, untreated hyperprolactinaemia
  • Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • Tested positive for Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
  • User of recreational or illicit drugs or has had a recent history (within the past year) of drug abuse or dependence, or increased alcohol consumption
  • Allergy/sensitivity to gonadotropins or its/their excipients
  • Has received within previous 1 month or plans to use: Hormonal preparations other than the study medication, drugs that are known to impair testicular function, agents known to affect sex hormone secretion and/or drugs that are known or suspected to be teratogenic
  • Used any investigational drugs within three months or actively participating in another study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01709331

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.

Publications of Results:
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT01709331     History of Changes
Other Study ID Numbers: P07937
2012-001258-25 ( EudraCT Number )
MK-8962-031 ( Other Identifier: Merck )
First Posted: October 18, 2012    Key Record Dates
Results First Posted: May 9, 2016
Last Update Posted: September 3, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonadal Disorders
Endocrine System Diseases
Chorionic Gonadotropin
Reproductive Control Agents
Physiological Effects of Drugs